M&A Deal Summary

Grünenthal Acquires Acorda Therapeutics - Qutenza

On November 5, 2018, Grünenthal acquired medical products company Acorda Therapeutics - Qutenza from Acorda Therapeutics

Acquisition Highlights
  • This is Grünenthal’s 2nd transaction in the Medical Products sector.
  • This is Grünenthal’s 2nd transaction in the United States.
  • This is Grünenthal’s 1st transaction in New York.

M&A Deal Summary
Date 2018-11-05
Target Acorda Therapeutics - Qutenza
Sector Medical Products
Buyer(s) Grünenthal
Sellers(s) Acorda Therapeutics
Deal Type Divestiture

Target

Acorda Therapeutics - Qutenza

Ardsley, New York, United States
Acorda Therapeutics, Inc. - Qutenza is a pain product. A single, 1-hour, localized treatment with this patch may provide at least 3 months of relief from for example post-shingles nerve pain.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Grünenthal

Aachen, Germany
Category Company
Sector Life Science
DESCRIPTION

Grünenthal GmbH is an independent, family-owned, international research-based pharmaceutical company.

DEAL STATS #
Overall 4 of 8
Sector (Medical Products) 2 of 2
Type (Divestiture) 1 of 2
State (New York) 1 of 1
Country (United States) 2 of 4
Year (2018) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-04-07 Adhesys Medical

Aachen, Germany

Adhesys Medical GmbH is a medical device company that focuses on developing polyurethane based surgical sealants for emergency procedures. Adhesys Medical GmbH was founded in 2013 and is based in Aachen, Germany.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-14 Averitas Pharma

Morristown, New Jersey, United States

Averitas Pharma, Inc. will be enhancing the commercial distribution model for Qutenza® towards a specialty pharmacy and hub services model that makes it easier for patients to access the product and support health care professionals in prescribing and applying it. Qutenza is a local analgesic and an alternative to the current standard of care, as there is still a high unmet medical need in pain management, particularly for non-opioid and non-systemic treatments. In Europe, it is approved for a broad peripheral neuropathic pain indication in adults, e.g. post-surgical neuropathic pain, cancer-related neuropathic pain, and painful diabetic peripheral neuropathy.

Buy -

Seller(S) 1

SELLER

Acorda Therapeutics

Pearl River, New York, United States
Category Company
Founded 1995
Sector Life Science
Employees102
Revenue 118M USD (2023)
DESCRIPTION

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis and related neurological conditions such as spinal cord injury (SCI). Acorda Therapeutics was founded in 1995 and is headquartered in Pearl River, New York.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 2
State (New York) 1 of 1
Country (United States) 1 of 2
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-19 Biotie Therapies

Turku, Finland

Biotie Therapies Corp. is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Its pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease.

Buy $363M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-13 Acorda Therapeutics - Manufacturing & Packaging Operations

Chelsea, Massachusetts, United States

Acorda Therapeutics' Manufacturing & Packaging Operations provides spray drying capacity, including GEA NIRO® PSD-1, PSD-4, and PSD-7 spray drying unit.

Sell -
Mergr

Product

Company

Legal